ERBB2 and breast carcinoma: Patient 018 in cohort 4 had multiple sub-cm brain metastases from ERBB2-amplified and ERBB3-mutated breast cancer and was treated on study after receiving docetaxel, trastuzumab, and pertuzumab for primary and metastatic disease along with cerebellar radiation.